Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2008 /
Continuing adjuvant tamoxifen leads to higher quality of life

10th - 14th Dec 2008

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.03.09
Views: 11331
Rating:

Dr Shozo Ohsumi - Chief of Breast Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan

After one to four years of tamoxifen, switching to anastrozole improves disease-free survival by about 31 percent, but patients pay a price in quality of life measures. The difference in quality of life is significant enough that scientists say it should be considered, and may even be the deciding factor, when making a clinical decision about therapeutic strategy.

Categories:

Breast SABCS 2008

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation